Jadwiga Wardas Selected Research

Harmaline

12/2021	The Pathophysiology and Treatment of Essential Tremor: The Role of Adenosine and Dopamine Receptors in Animal Models.
7/2020	Pramipexole Reduces zif-268 mRNA Expression in Brain Structures involved in the Generation of Harmaline-Induced Tremor.
1/2020	Inhibition of Excessive Glutamatergic Transmission in the Ventral Thalamic Nuclei by a Selective Adenosine A1 Receptor Agonist, 5'-Chloro-5'-Deoxy-(±)-ENBA Underlies its Tremorolytic Effect in the Harmaline-Induced Model of Essential Tremor.
5/2017	Tremorolytic effect of 5'-chloro-5'-deoxy-(±)-ENBA, a potent and selective adenosine A1 receptor agonist, evaluated in the harmaline-induced model in rats.
1/2016	Pramipexole at a Low Dose Induces Beneficial Effect in the Harmaline-induced Model of Essential Tremor in Rats.
6/2015	Apomorphine enhances harmaline-induced tremor in rats.
8/2014	Lu AF21934, a positive allosteric modulator of mGlu4 receptors, reduces the harmaline-induced hyperactivity but not tremor in rats.
9/2009	Role of the metabotropic glutamate receptor subtype 1 in the harmaline-induced tremor in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jadwiga Wardas Research Topics

Disease

17	Parkinson Disease (Parkinson's Disease) 01/2022 - 07/2002
9	Tremor (Tremors) 01/2022 - 09/2009
7	Essential Tremor (Essential Tremors) 12/2021 - 08/2014
6	Parkinsonian Disorders (Parkinsonism) 01/2022 - 11/2003
4	Catalepsy 05/2004 - 05/2003
3	Gliosis 01/2016 - 12/2009
2	Neuroinflammatory Diseases 01/2016 - 12/2013
2	Dyskinesias (Dyskinesia) 12/2007 - 11/2005
2	Muscle Rigidity 07/2003 - 03/2003
1	Nervous System Diseases (Neurological Disorders) 07/2020
1	Inflammation (Inflammations) 07/2013
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 09/2009
1	Gambling (Pathological Gambling) 09/2009
1	Ataxia (Dyssynergia) 09/2009
1	Schizophrenia (Dementia Praecox) 05/2008
1	Hypoxia (Hypoxemia) 07/2002
1	Ischemia 07/2002

Drug/Important Bio-Agent (IBA)

8	HarmalineIBA 12/2021 - 09/2009
7	Messenger RNA (mRNA)IBA 07/2020 - 05/2003
5	Adenosine (Adenocard)FDA LinkGeneric 12/2021 - 07/2002
5	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 12/2013 - 07/2002
4	Pharmaceutical PreparationsIBA 07/2020 - 03/2003
4	Pramipexole (Mirapex)FDA LinkGeneric 07/2020 - 09/2014
4	Levodopa (L Dopa)FDA LinkGeneric 12/2018 - 03/2003
4	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 03/2011 - 07/2002
3	Dopamine (Intropin)FDA LinkGeneric 12/2021 - 09/2009
3	Adenosine A1 ReceptorIBA 12/2021 - 05/2017
3	Neuroprotective AgentsIBA 12/2009 - 07/2002
3	5- amino- 7- (2- phenylethyl)- 2- (2- furyl)pyrazolo(4,3- e)- 1,2,4- triazolo(1,5- c)pyrimidineIBA 12/2009 - 03/2003
3	proenkephalinIBA 05/2004 - 05/2003
3	Haloperidol (Haldol)FDA LinkGeneric 05/2004 - 05/2003
2	Antidepressive Agents (Antidepressants)IBA 12/2018 - 09/2014
2	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)IBA 01/2016 - 12/2013
2	Dopamine Agonists (Dopamine Agonist)IBA 06/2015 - 09/2009
2	1,2,3,4-tetrahydroisoquinolineIBA 09/2009 - 11/2003
2	Glutamic Acid (Glutamate)FDA Link 09/2009 - 09/2009
2	Neurotransmitter Agents (Neurotransmitter)IBA 09/2009 - 05/2004
2	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 09/2009 - 05/2003
2	NeurotoxinsIBA 09/2009 - 05/2004
2	Adenosine A2 Receptor AntagonistsIBA 11/2005 - 07/2002
1	Antipsychotic Agents (Antipsychotics)IBA 01/2022
1	Dopamine Receptors (Dopamine Receptor)IBA 12/2021
1	1,3-dipropyl-8-cyclopentylxanthineIBA 05/2017
1	7-hydroxy-2-N,N-dipropylaminotetralinIBA 01/2016
1	Dopamine D3 ReceptorsIBA 01/2016
1	Caffeine (No Doz)FDA LinkGeneric 01/2016
1	Propranolol (Inderal)FDA LinkGeneric 06/2015
1	Apomorphine FDA Link 06/2015
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2015
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 11/2014
1	CytokinesIBA 11/2014
1	Imipramine (Janimine)FDA LinkGeneric 09/2014
1	Fluoxetine (Prozac)FDA LinkGeneric 09/2014
1	metabotropic glutamate receptor 4IBA 08/2014
1	N1- (3,4- dichlorophenyl)- cyclohexane- 1,2- dicarboxamideIBA 08/2014
1	Amphetamine (Amfetamine)FDA LinkGeneric 12/2013
1	Purinergic P1 Receptor AntagonistsIBA 07/2013
1	Proteasome InhibitorsIBA 06/2011
1	UbiquitinIBA 06/2011
1	Proteasome Endopeptidase Complex (Proteasome)IBA 06/2011
1	Proteins (Proteins, Gene)FDA Link 06/2011
1	lactacystinIBA 06/2011
1	2- n- butyl- 9- methyl- 8- (1,2,3)triazol- 2- yl- 9H- purin- 6- ylamineIBA 03/2011
1	AminesIBA 09/2009
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 09/2009
1	Dizocilpine Maleate (Dizocilpine)IBA 09/2009
1	metabotropic glutamate receptor type 1IBA 09/2009
1	Adenosine A2 Receptor AgonistsIBA 05/2008
1	ParaquatIBA 06/2007
1	istradefyllineIBA 11/2005
1	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 05/2005
1	PesticidesIBA 06/2004
1	1-methyl-1,2,3,4-tetrahydroisoquinolineIBA 06/2004
1	RotenoneIBA 06/2004
1	2- (4- (2- carboxyethyl)phenethylamino)- 5'- N- ethylcarboxamidoadenosineIBA 07/2003
1	AcidsIBA 05/2003
1	alpha-Methyltyrosine (Metirosine)FDA Link 03/2003
1	Reserpine (Serpasil)FDA Link 03/2003
1	Methamphetamine (Desoxyn)FDA LinkGeneric 07/2002

Therapy/Procedure

4	Therapeutics 12/2021 - 11/2005
1	Drug Therapy (Chemotherapy) 07/2020